Yatsen secures $120M via convertible notes with Trustar Capital

Yatsen agreed to issue RMB-denominated convertible senior notes totaling about $120M in two $60M tranches (1.5% coupon), with the first issuance ~March 2026 and an initial 364-day term that can extend to five years upon foreign debt registration. Notes convert at $4.63 (20% premium vs recent VWAP) and include warrants equal to 0.1 share per converted share at a $0.50 exercise price; holders can force a repurchase on year three targeting a 4% IRR. Company fundamentals are solid: current ratio 3.63, more cash than debt, 78.2% gross margin, 27% revenue growth LTM, and Q4 2025 revenue up 20.1% YoY to RMB 1.38B with Q1 2026 revenue guidance of RMB 958.6M–1.08B. The financing reduces near-term liquidity risk and supports R&D, supply-chain integration, overseas expansion and M&A, which is mildly positive for the equity despite a 64% six-month share price decline.

Analysis

The financing event materially changes the company's capital structure dynamics even if the mechanics are opaque to public investors: it shifts downside from existing shareholders toward holders of the new instrument while leaving an asymmetric equity kicker for those holders. That reduces near‑term liquidation risk for the business and increases runway for international expansion, which should compress visible short‑term volatility but create a latent, medium‑term dilution overhang that will dominate re‑rating moves.

Second‑order winners are non‑obvious: contract manufacturers, ingredient suppliers and cross‑border logistics partners that scale with export penetration will see leverage to the company’s overseas push without competing directly in retail. Conversely, smaller domestic indie brands that lack capital to internationalize will face faster consolidation; private equity and strategic acquirers are positioned to pick up assets at premium multiples, accelerating M&A activity in the sector over the next 12–24 months.

Key catalysts to watch are corporate guidance cadence, any regulatory milestone that converts contingent obligations into tradable equity, and analyst flow once profitability is demonstrated. Tail risks include regulatory or paperwork delays that push dilution further out (creating liquidity squeezes), or a margin erosion scenario if overseas distribution costs rise. The investment case is therefore a timing bet: limited near‑term downside courtesy of improved liquidity, with a replayable upside if execution on overseas channels and margin retention occur within 6–18 months.

Key Decisions for Investors

• Tactical directional (YSG): Buy a modest-sized 6–9 month call spread on YSG (2–4% portfolio) to capture a re‑rating if upcoming guidance and margins beat; target 2–3x on successful re‑rating, max downside = premium paid, stop if shares fall 30% from entry or if guidance misses materially.
• Credit/convertible access (private): If offered access to the new instrument, buy the paper at issuance with a 12–36 month horizon and hedge ~50–70% of equity delta via short stock or put options to lock in carry plus upside; target effective yield + optionality >300–500bps over comparable corporates, principal at risk if conversion/registration stalls.
• Sector pair (idiosyncratic vs growth): Reallocate a small portion of growth exposure into YSG versus high‑multiple US growth (e.g., trim APP/SMCI exposure by 1–2% and redeploy into YSG)—aim for asymmetric payoff from idiosyncratic recovery while reducing macro‑beta; horizon 6–18 months.
• Risk control: Use event triggers—trim/hedge if the regulatory registration milestone is not cleared within 12 months or if quarterly revenue misses consensus by >5%—and consider buying 12–18 month puts to cap tail loss if holding full equity exposure.